Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, January 30, 2018
Cambrex announced an investment to expand chemical and analytical development capabilities at its Charles City, Iowa plant.
read more
Cambrex announced it is investing $3.6 million at its Karlskoga, Sweden facility to increase flexible drug substance manufacturing capacity.
read more
Cambrex announced the completion of an investment project at its facility in Tallinn, Estonia to upgrade its kilogram-scale laboratory to undertake the manufacture of pharmaceutical intermediates under current good manufacturing practice (CGMP) ...
read more
Wednesday, August 09, 2017
Cambrex Corporation announced that it is to invest $24 million in a new facility to manufacture highly potent APIs (HPAPIs) at its Charles City, Iowa plant.
read more
Cambrex announced that it is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its site in Paullo, Milan, Italy.
read more
Wednesday, November 08, 2017
Cambrex announced that it has completed an expansion of cGMP small scale capacity at its Charles City, Iowa plant.
read more
Cambrex announced Tom Loewald has been named Chief Executive Officer and a member of the company’s Board of Directors, effective September 7th.
read more
Cambrex has announced three senior appointments to further support the Contract development and Manufacturing Organization company.
read more
Tuesday, November 20, 2018
Cambrex has entered into a definitive agreement to acquire Avista Pharma Solutions, a contract development, manufacturing, and testing organization, for approximately $252 million.
read more
Monday, November 21, 2022
Cambrex entered an agreement to acquire Snapdragon Chemistry, a leading US-based provider of chemical process development services to a broad range of emerging and established biopharma customers.
read more
Tuesday, September 25, 2018
Cambrex announced that it is to establish a center of excellence for API clinical supply and process development at its site in High Point, North Carolina.
read more
Wednesday, November 25, 2020
Cambrex is expanding its mid-scale and large-scale API manufacturing capacity in Charles City, Iowa.
read more
Thursday, October 07, 2021
Cambrex announced that it is expanding its manufacturing center of excellence in High Point, NC. The $30+ million investment is designed to meet the continually growing demand for small molecule development and manufacturing services.
read more
Wednesday, January 17, 2018
Cambrex held an opening ceremony with AstraZeneca at its Sweden site to mark the commencement of a long-term manufacturing agreement between the two companies for a key intermediate.
read more
Monday, November 04, 2013
Cambridge Major Laboratories, Inc. (“CML”), a global leader in pharmaceutical API development and manufacturing, and AAIPharma Services, Corp. (“AAIPharma”), a leading global provider of pharmaceutical analytical testing, product development and ...
read more